Immunotherapy in genitourinary cancers: Where are we going?

Maristella Bianconi, Luca Faloppi, Antonio Lopez-Beltran, Liang Cheng, Alessia Cimadamore, Silvia Gasparrini, Francesco Massari, Marina Scarpelli, Rodolfo Montironi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Tumour-associated inflammation is involved with the development of genitourinary cancers. A growing understanding of the interactions between immune cells and cancer provides the basis for immunomodulating approaches. Area covered: Immunotherapies targeting immune checkpoints and tumour-associated antigens are providing a new approach in patients with prostate and bladder cancer and renal cell carcinoma. The possibility to integrate such therapeutic agents in the current scenario, both in sequential or combined approaches, relies on a comprehension of the pro-tumourigenic activity of the immune system and the mechanisms of cancer-related immunosuppression. Expert commentary: Treatment of genitourinary cancers is being revolutionized by the recent development of new immunotherapeutic approaches. The next step will be the identification of the sequences or combinations between novel and effective immunotherapies and currently approved targeted agents and chemotherapies.

Original languageEnglish (US)
Pages (from-to)73-78
Number of pages6
JournalExpert Review of Precision Medicine and Drug Development
Volume2
Issue number2
DOIs
StatePublished - Jan 1 2017

Fingerprint

Urogenital Neoplasms
Immunotherapy
Neoplasms
Neoplasm Antigens
Renal Cell Carcinoma
Urinary Bladder Neoplasms
Immunosuppression
Immune System
Prostatic Neoplasms
Inflammation
Drug Therapy
Therapeutics

Keywords

  • Genitourinary tumours
  • Immunotherapy
  • Lymphocytes
  • Macrophages
  • Neutrophils
  • PD-L1 inhibitors
  • Resistance

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Bianconi, M., Faloppi, L., Lopez-Beltran, A., Cheng, L., Cimadamore, A., Gasparrini, S., ... Montironi, R. (2017). Immunotherapy in genitourinary cancers: Where are we going? Expert Review of Precision Medicine and Drug Development, 2(2), 73-78. https://doi.org/10.1080/23808993.2017.1321466

Immunotherapy in genitourinary cancers : Where are we going? / Bianconi, Maristella; Faloppi, Luca; Lopez-Beltran, Antonio; Cheng, Liang; Cimadamore, Alessia; Gasparrini, Silvia; Massari, Francesco; Scarpelli, Marina; Montironi, Rodolfo.

In: Expert Review of Precision Medicine and Drug Development, Vol. 2, No. 2, 01.01.2017, p. 73-78.

Research output: Contribution to journalArticle

Bianconi, M, Faloppi, L, Lopez-Beltran, A, Cheng, L, Cimadamore, A, Gasparrini, S, Massari, F, Scarpelli, M & Montironi, R 2017, 'Immunotherapy in genitourinary cancers: Where are we going?', Expert Review of Precision Medicine and Drug Development, vol. 2, no. 2, pp. 73-78. https://doi.org/10.1080/23808993.2017.1321466
Bianconi, Maristella ; Faloppi, Luca ; Lopez-Beltran, Antonio ; Cheng, Liang ; Cimadamore, Alessia ; Gasparrini, Silvia ; Massari, Francesco ; Scarpelli, Marina ; Montironi, Rodolfo. / Immunotherapy in genitourinary cancers : Where are we going?. In: Expert Review of Precision Medicine and Drug Development. 2017 ; Vol. 2, No. 2. pp. 73-78.
@article{5f2dd11c20e947619b9f5f3e2e9de800,
title = "Immunotherapy in genitourinary cancers: Where are we going?",
abstract = "Introduction: Tumour-associated inflammation is involved with the development of genitourinary cancers. A growing understanding of the interactions between immune cells and cancer provides the basis for immunomodulating approaches. Area covered: Immunotherapies targeting immune checkpoints and tumour-associated antigens are providing a new approach in patients with prostate and bladder cancer and renal cell carcinoma. The possibility to integrate such therapeutic agents in the current scenario, both in sequential or combined approaches, relies on a comprehension of the pro-tumourigenic activity of the immune system and the mechanisms of cancer-related immunosuppression. Expert commentary: Treatment of genitourinary cancers is being revolutionized by the recent development of new immunotherapeutic approaches. The next step will be the identification of the sequences or combinations between novel and effective immunotherapies and currently approved targeted agents and chemotherapies.",
keywords = "Genitourinary tumours, Immunotherapy, Lymphocytes, Macrophages, Neutrophils, PD-L1 inhibitors, Resistance",
author = "Maristella Bianconi and Luca Faloppi and Antonio Lopez-Beltran and Liang Cheng and Alessia Cimadamore and Silvia Gasparrini and Francesco Massari and Marina Scarpelli and Rodolfo Montironi",
year = "2017",
month = "1",
day = "1",
doi = "10.1080/23808993.2017.1321466",
language = "English (US)",
volume = "2",
pages = "73--78",
journal = "Expert Review of Precision Medicine and Drug Development",
issn = "2380-8993",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Immunotherapy in genitourinary cancers

T2 - Where are we going?

AU - Bianconi, Maristella

AU - Faloppi, Luca

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

AU - Cimadamore, Alessia

AU - Gasparrini, Silvia

AU - Massari, Francesco

AU - Scarpelli, Marina

AU - Montironi, Rodolfo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: Tumour-associated inflammation is involved with the development of genitourinary cancers. A growing understanding of the interactions between immune cells and cancer provides the basis for immunomodulating approaches. Area covered: Immunotherapies targeting immune checkpoints and tumour-associated antigens are providing a new approach in patients with prostate and bladder cancer and renal cell carcinoma. The possibility to integrate such therapeutic agents in the current scenario, both in sequential or combined approaches, relies on a comprehension of the pro-tumourigenic activity of the immune system and the mechanisms of cancer-related immunosuppression. Expert commentary: Treatment of genitourinary cancers is being revolutionized by the recent development of new immunotherapeutic approaches. The next step will be the identification of the sequences or combinations between novel and effective immunotherapies and currently approved targeted agents and chemotherapies.

AB - Introduction: Tumour-associated inflammation is involved with the development of genitourinary cancers. A growing understanding of the interactions between immune cells and cancer provides the basis for immunomodulating approaches. Area covered: Immunotherapies targeting immune checkpoints and tumour-associated antigens are providing a new approach in patients with prostate and bladder cancer and renal cell carcinoma. The possibility to integrate such therapeutic agents in the current scenario, both in sequential or combined approaches, relies on a comprehension of the pro-tumourigenic activity of the immune system and the mechanisms of cancer-related immunosuppression. Expert commentary: Treatment of genitourinary cancers is being revolutionized by the recent development of new immunotherapeutic approaches. The next step will be the identification of the sequences or combinations between novel and effective immunotherapies and currently approved targeted agents and chemotherapies.

KW - Genitourinary tumours

KW - Immunotherapy

KW - Lymphocytes

KW - Macrophages

KW - Neutrophils

KW - PD-L1 inhibitors

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=85054840441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054840441&partnerID=8YFLogxK

U2 - 10.1080/23808993.2017.1321466

DO - 10.1080/23808993.2017.1321466

M3 - Article

AN - SCOPUS:85054840441

VL - 2

SP - 73

EP - 78

JO - Expert Review of Precision Medicine and Drug Development

JF - Expert Review of Precision Medicine and Drug Development

SN - 2380-8993

IS - 2

ER -